Page last updated: 2024-09-03

elacridar and u 18666a

elacridar has been researched along with u 18666a in 1 studies

Compound Research Comparison

Studies (elacridar)	Trials (elacridar)	Recent Studies (post-2010) (elacridar)	Studies (u 18666a)	Trials (u 18666a)	Recent Studies (post-2010) (u 18666a)
284	8	119	207	0	77

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jansson, PJ; Richardson, DR; Seebacher, NA	1

Other Studies

1 other study(ies) available for elacridar and u 18666a

Article	Year
A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell death & disease, 2016, 12-01, Volume: 7, Issue:12 Topics: Acridines; Androstenes; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Nucleus; Cholesterol; Doxorubicin; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Intracellular Space; Lysosomes; Models, Biological; Permeability; Pyridines; Tetrahydroisoquinolines; Thiosemicarbazones	2016

Article

Year

A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC.

Cell death & disease, 2016, 12-01, Volume: 7, Issue:12

Topics: Acridines; Androstenes; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Nucleus; Cholesterol; Doxorubicin; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Intracellular Space; Lysosomes; Models, Biological; Permeability; Pyridines; Tetrahydroisoquinolines; Thiosemicarbazones

2016